Novel treatments for recurrent respiratory papillomatosis

Bibliography

• MORGAN AH, ZITSCH RP: Recurrent respiratory papillomatosis in children: a retrospective study of management and complications. Ear Nose Throat (1986) 65:19–28.
   PubMedGoogle Scholar
• DERKAY CS: Task force on recurrent respiratory papillomas. Arch. Otolaryngol Head Neck Surg. (1995) 121:1386–1391.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG LR DERKAY CS, REEVES WC: Initial results from the National Registry for juvenile-onset recurrent respiratory papillomatosis. Arch. Otolaryngol Head Neck Surg. (1999) 125:743–748.
   PubMed Web of Science ®Google Scholar
• DERKAY CS: Recurrent respiratory papillomatosis. Laryngoscope (2001) 111:57–69.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview covering several aspectsof RRP.
   Google Scholar
• COHN AM, KOS JT, TABER LH, ADAM E: Recurring laryngeal papilloma. Am. J. OtolaryngoL (1981) 2:129–132.
   PubMedGoogle Scholar
• MOUNTS P, SHAH KV, KASHIMA H: Viral etiology of juvenile and adult onset squamous papilloma of the larynx. Proc. Natl. Acad. Sci. USA (1982) 79:5425–5429.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG LR, PRESTON EJ, REICHERT M et al: Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin. Infect. Dis. (2000) 31(1): 107–109.
   PubMed Web of Science ®Google Scholar
• LINDBERG H, ELBROND 0: Laryngeal papillomas: the epidemiology in a Danish subpopulation: 1965-1984. Clin. OtolaryngoL (1991) 15:125–131.
   Web of Science ®Google Scholar
• STREET MD, TINDLE RW: Vaccines of human papillomavirus-associated anogenital disease and cervical cancer: practical and theoretical approaches. Expert Opin. Investig. Drugs (1999) 8(6):761–776.
   PubMedGoogle Scholar
• ••Excellent overview covering several aspectsof RRP.
   Google Scholar
• ALEXANDER KA, PHELPS WC: Recent advances in diagnosis and therapy of human papillomaviruses. Expert Opin. Investig. Drugs (2000) 9(8):1753–1765.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview covering several aspectsof RRP.
   Google Scholar
• SHIKOWITZ MJ, ABRAMSON AL, FREEMAN K, STEINBERG BM, NOURI M: Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope (1998) 108:962–967.
   PubMed Web of Science ®Google Scholar
• SHEN J, TATE JE, CRUM CP, GOODMAN ML: Prevalence of human papillomaviruses (HPV) in benign and malignant tumours of the upper respiratory tract. Mod. Pathol (1996) 9(1):15–20.
   PubMed Web of Science ®Google Scholar
• BLACKLEDGE FA, ANAND VK: Tracheobronchial extension of recurrent respiratory papillomatosis. Ann. Otol. Rhino]. Laryngol (2000) 109(9):812–818.
   PubMed Web of Science ®Google Scholar
• •Describes the course of RRP in a large group of 52 patients.
   Google Scholar
• PURANEN M, YLINKOSKI M, SAARIKOSKI S, SYRJANEN K, SYRJANEN S: Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am. J. Obstet. Cynecol (1996) 174:694–699.
   PubMed Web of Science ®Google Scholar
• TSENG C, LIANG C, SOONG Y, PAO C: Perinatal transmission of human papillomavirus in infants: relationship between rate and mode of delivery. Obstet. Cynecol (1998) 91:92–96.
   Web of Science ®Google Scholar
• SMITH EM, JOHNSON SR, PIGNAARI S, CRIPE TP, TUREK L: Perinatal vertical transmission of human papilloma virus and subsequent development of respiratory tract papillomatosis. Ann. Otol. Rhino]. Laryngol (1991) 100:479–483.
   PubMed Web of Science ®Google Scholar
• SHAH K, KASHIMA H, POLK BF, SHAH F, ASBBEY H, ABRAMSON A: Rarity of caesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet. Cynecol (1986) 68:795–799.
   Web of Science ®Google Scholar
• TENTI P, ZAPPATORE R MIGLIORA P, SPINILLO A, BELLONI C, CARNEVALLI L: Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet. Cynecol (1999) 93:475–479.
   Web of Science ®Google Scholar
• •Deals with preventative strategies in 711 preganant women.
   Google Scholar
• SNOECK R, WELLENS W, DESLOOVERE C et al.: Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S) 1 (3 Hydroxy-2-Phosphonylmethoxypropyl) cytosine] . J. Med. ViroL (1998) 54:219–225.
   PubMed Web of Science ®Google Scholar
• •Presents data concerning the use of the new treatment strategy, intralesional cidofovir, in 17 patients.
   Google Scholar
• ARMBRUSTER C, KREUZER A, VORBACH H, HUBER M, ARMBRUSTER C: Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon a-2b. Ear: Respir. (2001) 17:830–831.
   PubMed Web of Science ®Google Scholar
• KRAMER S, WEHUNT W, STOCKER JT, KASHIMA H: Pulmonary manifestations of juvenile laryngotracheal papillomatosis. ARJ Am. J. Roentgenol (1985) 144:687–694.
   PubMed Web of Science ®Google Scholar
• MAGID M, CHEN YT, SOSLOW R, BOULAD F, KERNAN N, SZABOLCS P: Juvenile-onset recurrent respiratory papillomatosis involving the lung: a case report and review of the literature. Pediatr. Dev. Pathol (1998) 1:757–763.
   Web of Science ®Google Scholar
• COOK JR, HILL A, HUMPHREY PA, PFEIFER JP, EL-MOFTY SK: Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol (2000) 13:914–918.
   PubMed Web of Science ®Google Scholar
• YOUSEM SA, OHORI NP, SONMEZ-ALPAN E: Occurrence of human papillomavirus DNA in primary lung neplasms. Cancer (1992) 69:693–697.
   PubMed Web of Science ®Google Scholar
• RIMELL FL, SHOEMAKER DL, POU AM, JORDAN JA, POST CJ, EHRLICH GD: Pediatric respiratory papillomatosis: prognostic role of viral subtyping and cofactors. Laryngoscope (1997) 107:915–918.
   PubMed Web of Science ®Google Scholar
• PENALOZA-PLASCENCIA M, MONTOYA-FUENTES H, FLORES-MARTINEZ SE, FIERRO-VELASCO FJ, PENAL OZA-GONZALEZJM, SANCHEZ-CORONA J: Molecular identification of 7 human papillomavirus types in recurrent respiratory papillomatosis. Arch. Otolaryngol Head Neck Stag. (2000) 126(9):1119–1123.
   PubMed Web of Science ®Google Scholar
• RABAH R, LANCASTER WD, THOMAS R GREGOIRE L: Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediam Dev. Pathol (2001) 4(1):68–72.
   PubMed Web of Science ®Google Scholar
• SNOWDEN RT, THOMPSON J, HORWITZ E, STOCKS RM: The predictive value of serum interleukins in recurrent respiratory papillomatosis: a preliminary study. Laryngoscope (2001) 111(3):404–408.
   PubMed Web of Science ®Google Scholar
• BONAGURA VR, HATAM L, DE VOTI J, ZENG F, STEINBERG BM: Recurrent respiratory papillomatosis: altered CD8+ T-cell subsets and TH1/TH2 cytokine imbalance. Clin. ImmunoL (1999) 93(3):302–311.
   PubMed Web of Science ®Google Scholar
• DI LORENZO TP, TAMSEN A, ABRAMSON AL, STEINBERG BM: Human papillomavirus Type 6a DNA in the lung carcinoma of a patient with recurrent laryngeal papillomatosis is characterized by a partial duplication. J. Gen. Viral. (1992) 73:423–428.
   PubMed Web of Science ®Google Scholar
• SCHWERER MJ, SAILER A, KRAFT K, BACZAKO K, MAIER H: Differentiation-related p53 protein expression in nondysplastic sinonasal inverted papillomas. Am. J. Rhino]. (2001) 15(5):347–351.
   PubMedGoogle Scholar
• GUPTA D, HOLDEN J, LAYFIELD L: Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis. Appl. Immunohistochem. MM. Morphol (2001) 9(1):86–91.
   PubMed Web of Science ®Google Scholar
• AUBORN K, ABRAMSON A, BRADLOW HL, SEPKOVIC D, MULLOOLY V: Estrogen metabolism and laryngeal papillomatosis: a pilot study on dietary prevention. Anti-Cancer Res. (1998) 18(6B):4569–4573.
   Google Scholar
• KASHIMA H, LEVENTHAL B, MOUNTS P: Papilloma Study Group. Scoring system to assess severity and course in recurrent respiratory papillomatosis. In: Papillomavimses: molecular and clinical aspects. Howley PM, Broker TR (Eds.), Alan R. Liss, New York, USA (1985):125–135.
   Google Scholar
• DERKAY CS, MALIS DJ, ZALZAL G, WIATRAK BJ, KASHIMA HK, COLTRERA MD: A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope (1998) 108:935–937.
   PubMed Web of Science ®Google Scholar
• •Paper detailing the scoring system, set up by Derkay et al., which is necessary to accurately evaluate disease severity.
   Google Scholar
• STRONG MS, VAUGHAN CW, COOPERBAND SR HEALY GB, CLEMENTE MA: Recurrent respiratory papillomatosis. Management with CO2 laser. Ann. Otol Rhino]. Laryngol (1976) 85:508–516.
   PubMed Web of Science ®Google Scholar
• DEDO HH, YU KC: CO2 laser treatment in 244 patients with respiratory papillomatosis. Laryngoscope (2001) 111(9):1639–1644.
   PubMed Web of Science ®Google Scholar
• •Describes laser therapy in a large cohort of 244 patients.
   Google Scholar
• BERGLER W, HONIG M, GOTTE K, PETROIANU G, HORMANN K: Treatment of recurrent respiratory papillomatosis with argon plasma coagulation. Laryngol Otol (1997) 111:381–384.
   PubMed Web of Science ®Google Scholar
• BOWER CM, WANER M, FLOCK S, SCHAEFFER R: Flash pump dye laser treatment of laryngeal papillomas. Ann. Otol Rhino]. Laryngol (1998) 107:1001–1005.
   PubMed Web of Science ®Google Scholar
• McMILLAN K, SHAPSHAY SM, McGILLIGAN JA, WANG Z, REBEIZ EE: A 585 nanometer pulsed dye laser treatment of laryngeal papillomas: preliminary report. Laryngoscope (1998) 108:968–972.
   PubMed Web of Science ®Google Scholar
• EL-BITAR MA, ZALZAL GH: Powered instrumentation in the treatment of recurrent respiratory papillomatosis: an alternative to the carbon dioxide laser. Arch. Otolaryngol Head Neck Surg. (2002) 128(4):425–428.
   PubMed Web of Science ®Google Scholar
• STEINBERG BM, TOPP W, SCHNEIDER PS, ABRAMSON AL: Laryngeal papilloma virus infection during clinical remission. N Engl. J. Med. (1983) 308:1261–1264.
   PubMed Web of Science ®Google Scholar
• STEINBERG BM, GALLAGHER T, STOLER M, ABRAMSON AL: Persistence and expression of human papillomavirus during interferon therapy. Arch. Otolaryngol Head Neck Surgery(1988) 114(1):27–32.
   PubMed Web of Science ®Google Scholar
• JESIONEK A, TAPPEINER VH: Zur Behandlung der hautcarcinome met fluoreceincenden Stoffen. Muench. Med. Wochenschr. (1903) 47:2042–2044.
   Google Scholar
• SHIKOWITZ MJ, STEINBERG BM, ABRAMSON AL: Haematoporhyrin derivative therapy of papillomas. Arch. Otolaryngol Head Neck Surg. (1986) 112:42–
   PubMed Web of Science ®Google Scholar
• •Evaluates the first use of photodynamic therapy in humans suffering from RRP and set up animal models.
   Google Scholar
• ABRAMSON AL, BARREZUETA NX, SHIKOWITZ MJ: Thermal effects of photodynamic therapy on the larynx. Arch. Otolaryngol Head Neck Surg. (1987) 113:854–858.
   PubMed Web of Science ®Google Scholar
• •Evaluates the first use of photodynamic therapy in humans suffering from RRP and set up animal models.
   Google Scholar
• ABRAMSON AL, SHIKOWITZ MJ, MULLOOLY VM, STEINBERG BM, HYMAN RB: Variable light-dose effect on photodynamic therapy for laryngeal papillomas. Arch. Otolaryngol Head Neck Surg. (1994) 120(8):852–855.
   PubMed Web of Science ®Google Scholar
• HEALY GB, GELBER RD, TROWBRIDGE AL, GRUNFAST KM, RUBEN RJ, PRICE KN: Treatment of recurrent respiratory papillomatosis with human leukocyte interferon: results of a multicenter randomized clinical trial. N Engl. J. Med. (1988) 319:401–407.
   PubMed Web of Science ®Google Scholar
• HAGLUND S, LUNDQUIST PG, CANTELL K, STRANDER H: Interferon therapy in juvenile laryngeal papillomatosis. Arch. Otolaryngol (1981) 107:327–332.
   PubMed Web of Science ®Google Scholar
• GOEPFERT H, SESSIONS RB, GUTTERMAN JU, CANGIR A, DICHTEL WJ, SULEK M: Leukocyte interferon in patients with juvenile laryngeal papillomatosis. Ann. Otol Rhino]. Laryngol (1982) 91:431–436.
   PubMed Web of Science ®Google Scholar
• McCABE BF, CLARK KF: Interferon and papillomatosis. The Iowa experience. Ann. Otol Rhino]. Laryngol (1983) 92:2–7.
   PubMed Web of Science ®Google Scholar
• LEVENTHAL BG, KASHIMA HK, MOUNTS P et al.: Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-nl. N Engl. J. Med. (1991) 325:613–617.
   PubMed Web of Science ®Google Scholar
• MILLER RL, IMBERTSON LM, REITER MJ, GERSTER JF: Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antiviral Res. (1999) 44(1):31–42.
   PubMed Web of Science ®Google Scholar
• WEEKS CE, GIBSON SJ: Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells M vitro. .1. Interferon Res. (1994) 14:81–85.
   PubMedGoogle Scholar
• TOMAI MA, IMBERTSON LM, STANCZAK TL, TYGRETT LT, WALDSCHMIDT TJ: The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol (2000) 203(1):55–65.
   PubMed Web of Science ®Google Scholar
• MILLER RL, GERSTER JF, OWENS ML, SLADE HB, TOMAI MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol (1999) 21(1):1–14.
   PubMed Web of Science ®Google Scholar
• EDWARDS L, FERENCZY A, ERON L, BAKER D, OWENS ML, FOX TL, HOUGHAM AJ, SCHMITT KA: Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human papilloma virus. Arch. Dermatol (1998) 134(1):25–30.
   PubMed Web of Science ®Google Scholar
• FIFE KH: New treatments for genital warts less than ideal: Abstract and commentary. I Am. Med. Assoc. (1998) 279:2003–2004.
   PubMedGoogle Scholar
• McGLENNEN RC, ADAMS GL, LEWIS CM, FARAS AJ, OSTROW RS: Pilot trial of ribavirin for the treatment of laryngeal papillomatosis. Head Neck (1993) 15(6)504–512.
   Google Scholar
• GILBERT BE, WILSON SZ, KNIGHT Vet al.: Ribavirin small particle aerosol treatment of infections caused by influenza virus strain A/Victoria/7/83 (H1N1) and B/ Texas/1/84. Antimicrob. Agents Chemother. (1985) 27:309–313.
   Google Scholar
• GELFAND EW, McCURDY D, RAO CP, MIDDLETON PJ: Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease. Lancet (1983) 2:732–733.
   PubMed Web of Science ®Google Scholar
• McHUTCHINSON JG, GORDON SC, SCHIFF ER et al: Interferon alpha 2B alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl. Med. (1998) 339:1485–1492.
   PubMed Web of Science ®Google Scholar
• STREETER DG, WITKOWSKI JT, KHARE GP et al.: Mechanism of action of 1-B-D-ribofuranosy1-1,2,4-triazole-3-caroxamide (virazole), a new broad-spectrum antiviral agent. Proc. Nati Acad. Sci. USA (1973) 70:1174–1178.
   PubMed Web of Science ®Google Scholar
• NING Q, BROWN D, PARODO J et al: Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, procoagulant activity of fg 12 prothrombinase and preserves TH1 cytokine production but inhibits TH2 response. Immunol (1998) 160:3487–3493.
   Web of Science ®Google Scholar
• MORRISON GA, KOTECHA B, EVANS JN: Ribavirin treatment for juvenile respiratory papillomatosis. ./. Laryngol Otol (1993) 107(5):423–426.
   PubMed Web of Science ®Google Scholar
• POU AM, RIMELL FL, JORDAN JA et al.: Adult respiratory papillomatosis: human papillomavirus type and viral co-infections as predictors of prognosis. Am. Otol Rhino]. Laryngol (1995) 104:758–762.
   PubMed Web of Science ®Google Scholar
• SNOECK R ANDREI G, DE CLERCQ E: Cidofovir in the treatment of HPV-associated lesions. Verh. K. Acad. Ceneeskd. Belg. (2001) 63(2):93–120.
   PubMedGoogle Scholar
• ANDREI G, SNOECK R, SCHOLS D, DE CLERQ E: Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Omni Res. (2001) 12(9-10):397–408.
   Google Scholar
• CHRISTENSEN ND, PICKEL MD, BUDGEON LR, KREIDER JVV: ha vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res. (2000) 48(2):131–142.
   PubMed Web of Science ®Google Scholar
• PRANSKY SM, BREWSTER DF, MAGIT AE, KEARNS DB : Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch. Otolaryngol Head Neck Surg. (2000) 126(10):1239–1243.
   PubMed Web of Science ®Google Scholar
• WILSON WR, HASHEMIYOON R, HAWRYCH A: Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report. Ear Nose Throat (2000) 79(4):236–238, 240.
   Google Scholar
• VAN VALCKENBORGH I, WELLENS W, DE BOECK K, SNOECK R DE CLERCQ E, FEENSTRA L: Systemic cidofovir in papillomatosis. Clin. Infect. Dis. (2001) 32(3):E62–E64.
   PubMed Web of Science ®Google Scholar
• DANCEY DR, CAMBERLAIN DW, KRAJDEN M, PALEFSKYJ, ALBERTI PW, DOWNEY GP: Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir. Chest (2000) 118(4):1211–1214.
   Web of Science ®Google Scholar
• ROSEN CA, WOODSON GE, THOMPSON JW, HENGESTEG AP, BRADLOW HL: Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Sorg. (1998) 118(6):810–815.
   PubMed Web of Science ®Google Scholar
• HARCOURT JP, WORLEY G, LEIGHTON SE: Cimetidine treatment for recurrent respiratory papillomatosis. Int.' Pediatr. Otorhinolaryngol (1999) 51(2):109–113.
   PubMed Web of Science ®Google Scholar
• BORKOWSKI G, SOMMER P, STARK T, SUDHOFF H, LUCKHAUPT H: Recurrent respiratory papillomatosis associated with gastroesophageal reflux disease in children. Eur: Arch. Otorhinolaryngol (1999) 256(7):370–372.
   PubMed Web of Science ®Google Scholar
• TINDLE RW: Immunomanipulation strategies for the control of human papillomavirus associated cervical cancer. Immunol Res. (1997) 16:387–400.
   PubMed Web of Science ®Google Scholar
• RESSING ME, SETTE A, BRANDT RM et al: Human CTL epitopes encoded with human papillomavirus Type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-*A0201-binding peptides. I Immunol (1995) 154:5934–5943.
   PubMed Web of Science ®Google Scholar
• BORYSIEWICZ LK, FIANDER A, NIMAKO M et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 as immunotherapy for cervical cancer. Lancet (1996) 347:1523–1527.
   PubMed Web of Science ®Google Scholar
• ALBERICO S, PINZANO R, COMAR M, TOFFOLETTI F, MASO G, RICCI G, GUASCHINO S: Maternal-fetal transmission of human papillomavirus. Minerva Cinecol (1996) 48(5):199–204.
   PubMedGoogle Scholar
• SHAH KV, STERN WF, SHAH FK, BISHAI D, KASHIMA HK: Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr. Infect. Dis. (1998) 17(5):372–376.
   Google Scholar
• BISHAI D, KASHIMA H, SHAH K: The cost of juvenile-onset recurrent respiratory papillomatosis. Arch. Otolaryngol Head Neck Surg. (2000) 126(8):935–939.
   PubMed Web of Science ®Google Scholar
• 83. KOSKO JR, DERKAY CS: Role of caesarean section in prevention of recurrent respiratory papillomatosis-is there one? Int. Pediatr. Otorhinolaryngol (1996) 35(1):31–38.
   Google Scholar
• BEUTNER KR, FERENCZY A: Therapeutic approaches to genital warts. Am. Med. (1997) 102(5A):28–37.
   Google Scholar
• ARMBRUSTER C, STIEGLER GM, VCELAR BA et al: A Phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS (2002) 16:227–233.
   PubMed Web of Science ®Google Scholar